Navigation Links
KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
Date:10/11/2007

activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.

KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.

For further information about KineMed, please visit: http://www.kinemed.com/


'/>"/>
SOURCE KineMed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. KineMed Presents Data Measuring Changes in Reverse Cholesterol Transport for the First Time
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... YORK and KISSING, Germany ... and distributor of a single use and computer-assisted ("robotic") ... (Homi) Shamir , a worldwide recognized medical device executive, ... Mr. Shamir is a highly respected global ... recent assignment he served as President and Chief Executive ...
(Date:7/30/2014)... 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: DIGP), ... the cannabis testing and education markets, announced today that ... affairs not previously disclosed or, to its knowledge, any ... action. "We have noticed unusual price and ... trading days," said Steve Barbee , CEO of ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
Breaking Medicine Technology:invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 2invendo medical Appoints Nachum (Homi) Shamir To The Company's Board Of Directors 3DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3
... Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ), ... and gastroenterology markets, today announced that it has entered ... a new Phase II development product. The Company has ... Injection and is evaluating the product for the treatment ...
... Inc. (NYSE: CRY ), an implantable biological ... that 2011 first quarter financial results will be released ... Company will hold a teleconference call and live webcast ... followed by a question and answer session hosted by ...
Cached Medicine Technology:Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results 2
(Date:7/30/2014)... well as evolutionary changes in a living organismhad been ... the genome. , However, recent studies have shown that ... that arise simultaneously and in close proximity to each ... in regions where chromosomal rearrangements take place. , The ... may one day lead to new cancer therapies, according ...
(Date:7/30/2014)... 30, 2014 Hamilton Facial Plastic ... its new Carmel office on July 30th. After months ... be moving to the state-of-the-art suite, located only steps ... space will allow for one-on-one patient comfort, shorter wait ... , Dr. Hamilton’s new office-suite will continue to ...
(Date:7/30/2014)... NJ. July 30, 2014. A new network of 25 ... Stroke Trials Network (NIH StrokeNet) is working to ... U.S. Despite advances of the last two decades, ... stroke causes death or disability for 795,000 Americans. The ... of the population. , To accelerate the pace ...
(Date:7/30/2014)... Over 630 doctors worldwide are now certified ... minimally invasive treatment for gum recession. Santa Barbara, CA ... peers to be the “father of microsurgery” in periodontics ... Pinhole Surgical Technique® training course at the Chao Pinhole ... of the American Academy of Periodontics (AAP) 2010 Master ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Children’s Hospital ... celebrate Safety Day from 4 p.m. to 7 p.m. ... (29580 7 Mile Road, Livonia, MI 48152). The event ... bike helmets, children’s activities, music, snacks and local public ... to the Children’s Hospital of Michigan Foundation. , ...
Breaking Medicine News(10 mins):Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Kessler funded as satellite site for NIH Stroke Trials Network 2Health News:Periodontist Dr. Dennis Shanelec Comments On The Chao Pinhole Surgical Technique® Training Course 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 2Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 3Health News:Kohl’s, Children’s Hospital of Michigan Foundation Host Safety Day with Detroit Red Wings Defenseman Danny DeKeyser, Bike Helmets, Family Activities and More 4
... guidelines show half to two-thirds of women of childbearing ... News) -- A new study says federal guidelines on ... the category of "obese." , U.S. guidelines determine who ... whether a person,s height and weight are proportional. The ...
... much control a person has over their own health outcomes. ... when doctor and patient attitudes on the issue match up, ... Published online and in the May issue of the ... of a growing body of evidence indicating that patient-physician compatibility ...
... fewer side effects, experts say, , WEDNESDAY, April 21 (HealthDay ... promise in early testing as a possible new treatment for ... It,s too early to tell if the drug actually works, ... federal approval to be prescribed to patients. Still, the drug ...
... power, according to Penn State researchers who will test ... to help them manage their disease. The project, ... Chris Sciamanna, professor, department of medicine, Penn State College ... Lung and Blood Institute as part of the National ...
... ... , ... (Vocus) April 21, 2010 -- SafeShot Technologies, LLC , a leader in safety ... Emeritus Professor of Surgery at Keck School of Medicine, University of Southern California. Dr. ...
... D.C. Women who have a breast density of 75 ... breast cancer that is four to five times greater than ... breast density one of the strongest biomarkers of breast cancer ... 101st Annual Meeting 2010, held in Washington, D.C., April 17-21, ...
Cached Medicine News:Health News:More U.S. Women May Be Obese Than Thought 2Health News:Patient-physician compatibility increases odds of following doctor's orders 2Health News:Patient-physician compatibility increases odds of following doctor's orders 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Knowledge is power in Penn State blood pressure study 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 2Health News:SafeShot Technologies Names Dr. Robert W. Beart as New Chief Executive Officer 3Health News:Mammographic density and risk of breast cancer 2Health News:Mammographic density and risk of breast cancer 3Health News:Mammographic density and risk of breast cancer 4Health News:Mammographic density and risk of breast cancer 5
Subretinal Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 35°....
Silicone Oil Cannula; 16g (1.40) x 8mm....
Injection Cannula, Straight; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30)....
...
Medicine Products: